Long-term follow-up of people who received an investigational gene-editing therapy for heart disease
Follows adults who received a gene-editing therapy for high cholesterol and heart disease.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up of Participants Dosed With an Investigational Gene Editing Therapy for Cardiovascular Disease
Key facts
- Where
- London, United KingdomSee the site
Where in United Kingdom
- Clinical Study CenterLondon, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Verve Therapeutics, Inc.
- Trial code
- NCT06112327
- Record updated
- 8 April 2026
- Original description
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.Read full original descriptionShow less
Long-term Follow-up Study of Investigational Gene-editing Therapies in Participants With or at High Risk for Cardiovascular Disease
LTF-001 is a long-term follow-up study of participants who received an investigational gene-editing therapy developed by the sponsor to evaluate the long-term effects of the investigational therapy. Participants will be followed for a total of 15 years after the first administration of the gene-editing therapy.
Inclusion: A participant has completed or discontinued from a Verve sponsored clinical study in which they received at least one dose of study drug; A participant has provided informed consent for LTF-001.